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Abstract: Pain, which afflicts up to 20% of the population
at any time, provides both a massive therapeutic
challenge and a route to understanding mechanisms in
the nervous system. Specialised sensory neurons (noci-
ceptors) signal the existence of tissue damage to the
central nervous system (CNS), where pain is represented
in a complex matrix involving many CNS structures.
Genetic approaches to investigating pain pathways using
model organisms have identified the molecular nature of
the transducers, regulatory mechanisms involved in
changing neuronal activity, as well as the critical role of
immune system cells in driving pain pathways. In man,
mapping of human pain mutants as well as twin studies
and association studies of altered pain behaviour have
identified important regulators of the pain system. In turn,
new drug targets for chronic pain treatment have been
validated in transgenic mouse studies. Thus, genetic
studies of pain pathways have complemented the
traditional neuroscience approaches of electrophysiology
and pharmacology to give us fresh insights into the
molecular basis of pain perception.
Introduction
Noxious environmental stimuli, tissue damage, and disease all
evoke pain. The avoidance of painful stimuli, the protection of
damaged tissue to promote healing, and the amelioration of
disease-evoked pain (preferably through resolution of the disease
itself) have obvious survival value. The evolutionary utility of pain-
evoked behavioural responses is confirmed by apparent conserva-
tion of some mechanisms in all animals with nervous systems. The
existence of specialised mammalian sensory neurons that respond
to tissue damage (nociceptors), first proposed by Sherrington a
century ago, has been clearly demonstrated in humans and mice,
where mutations leading to loss of responsiveness to the trophic
factor nerve growth factor (NGF) result in the loss of nociceptive
neurons and a pain-free phenotype [1].
In this review we focus on genetic approaches to the
mechanisms involved in activating nociceptive neurons, human
genetics of pain perception, and genetic validation of pain targets
leading to new drugs. The application of molecular genetics to the
problem of pain has provided some remarkable insights over the
past 15 years [2]. Nonetheless, the scale of the clinical problem of
dysfunctional chronic pain remains vast (see for example http://
www.europeanpainnetwork.com/). New drugs acting on targets
validated in mouse and man by genetic studies show promise for
many of the present clinical problems. This therapeutic challenge
is complemented by the fact that pain also provides a wonderful
model system to understand how the nervous system works. This
area is perhaps the most exciting for geneticists who want to
address mechanisms of perception and consciousness, neuronal
signalling, synaptic plasticity, and integrative aspects of nervous
system function.
The Pain System
Figure 1 summarises the basic wiring and defined genes
involved in the pain system. Unlike other sensory modalities, such
as vision, hearing, and smell, the brain regions associated with pain
perception are complex and have been best described as a pain
matrix [3]. Given the uncertainty about central representation of
pain sensation, it is not surprising that most research activity has
focused on genes expressed by specialised peripheral sensory
neurons essential for pain. The mechanisms by which noxious
stimuli activate sensory neurons are summarised in Box 1. Spinal
cord plasticity and descending circuits that regulate noxious input
to the thalamus and higher brain centres have been examined in
detail at the systems level, but genetic approaches to understand-
ing CNS pain pathways are still at an early stage. The relationship
between CNS pain perception and the activation of damage
sensing neurons is complex, but most studies have focused on the
more tractable aspects of peripheral pain pathways.
Peripheral Pain Pathway Neurotransmission
Tissue damage depolarises sensory neurons, but the transmis-
sion of information to the CNS requires the recruitment of
voltage-gated sodium channels to propagate action potentials, and
cause neurotransmitter release (mainly glutamate) into the CNS
(Figure 1). In the absence of selective antagonists of ion channels,
knock-out mouse studies have provided important insights into the
genes that underlie this first stage in the induction of pain [4].
Three genes encoding sodium channels are selectively expressed in
sensory neurons. One, SCN11A, is found in a subset of damage-
sensing neurons, and is activated close to the resting membrane
potential. Knock-out studies have confirmed that the encoded
channel NaV1.9 does not support action potentials but plays a key
role in setting pain thresholds, as it is regulated by inflammatory
mediators [5]. The second, SCN9A, is essential for peripheral pain
and had been analysed in mouse knock-outs [6] before the
discovery of naturally occurring human mutants [7]. Global
mouse knock-outs of SCN9A die, probably because they are unable
to feed. However, nociceptor-specific null mutants show a loss of
acute mechanical and inflammatory pain [6]. Interestingly, loss of
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Figure 1. Genes Involved in Pain Perception and Modulation. Noxious stimuli are detected by primary afferent neurons innervating the skin,
muscle, and viscera. The cell bodies of these damage-sensing neurons (nociceptors) are found in dorsal root ganglia, except for neurons innervating
craniofacial tissues, which have cell bodies in the trigeminal ganglia. Nociceptors are commonly divided into three groups: peptidergic (blue, NGF-
responsive) and nonpeptidergic (black, GDNF-responsive) unmyelinated C-fibres, and myelinated Ad-fibres (red, NGF-responsive). Gene expression
profiles differ between these groups, with functional distinctions (reviewed in [62]). Specialised receptors, expressed in the peripheral termini of these
neurons, allow noxious stimuli to be transduced into electrical impulses. While the majority of nociceptors are polymodal (they can detect a variety of
noxious stimuli), specific receptors exist for each stimulus modality. The receptors for certain modalities, including mechanical and heat damage, are
currently unidentified, although several promising candidates have been proposed. In particular, specific TRP channels appear to be involved in
transduction of several stimulus modalities (e.g., [56,57,63,64]). The local membrane depolarisation generated by stimulus transduction is transmitted
along the axon by voltage-gated sodium channels, some of which are expressed specifically in nociceptors. The channels NaV1.7 (SCN9A) and NaV1.8
(SCN10A) have both been shown to play an important role in nociceptive transmission [6,7,11]. Transmission is modulated by the actions of
potassium channels, which generally act to reduce excitability. Regulation of spike frequency by potassium channels has also been reported. The
sensitivity of both transduction and action potential transmission by nociceptors can be altered by inflammatory and other mediators, released by
immune system cells and damaged neurons. This modulation is an important component of inflammatory hyperalgesia and neuropathic allodynia, in
which neuronal sensitivity is greatly increased. Nociceptors terminate in laminae 1 (Ad-fibres) and 2 (C-fibres) of the spinal cord dorsal horn, forming
synapses with nociceptive-specific spinal projection neurons. Some also synapse with wide dynamic range projection neurons in lamina 5, while light
touch neurons synapse in deeper laminae. Synaptic transmission occurs through NMDA, AMPA, and kainate receptors, in addition to neuropeptide
and proton-mediated transmission. Neurotransmitter release is controlled by voltage-gated Ca2+ channels in the presynaptic membrane. Regulation
of synaptic strength is achieved by many mechanisms, including long-term potentiation, whereby repeated activity within a frequency range results
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function SCN9A human mutants that have a defective NaV1.7
channel appear to be completely pain free but are otherwise
normal. This observation [7] is an important breakthrough in
terms of novel target validation for new classes of sodium channel
selective analgesic drugs. As an interesting corollary of this
observation, human gain of function mutations of SCN9A,
resulting in lowered thresholds of activation, result in erythermal-
gia, a chronic inflammatory condition. Rarer mutations that
impede the inactivation of the channel seem to cause acute
paroxysmal pain [8,9]. Finally SCN10A (NaV1.8), a specific marker
for nociceptive neurons, is a major contributor to electrogenesis in
primary pain pathways, and is an important target for inflamma-
tory mediators. It is also essential for cold pain [10,11].
Regulation of sodium channel expression, both transcriptionally
and posttranscriptionally, is an important element in determining
neuronal excitability. A short sequence found upstream of
neuronal sodium channel genes (as well as other neuronal genes)
was identified and named NRSE (Neuron restricted silencing
element) or RE-1 (repressor element 1) [12,13]. Transcription
factors that bound to the motif were found to act as inhibitors of
gene expression in non-neuronal cells. These proteins were named
REST (RE-1 silencing transcription factor), or NRSF (Neuron-
restrictive silencer factor). The inhibitory activity of the complex
can be further modulated by double-stranded RNA molecules that
have the same sequence as NRSE/RE-1, and are found in
developing neuronal precursors. These regulatory RNA molecules
are able to switch the repressor function of the complex to an
activator role [14]. Splicing and editing are also important
regulatory elements in controlling sodium channel function.
Editing events in cockroach sodium channels and Drosophila Para
have been correlated with functional changes. Liu et al. [15] have
shown that a U to C editing event resulting in a phenylalanine to
serine modification can produce a sodium channel with persistent
tetrodotoxin (TTX)–sensitive properties, raising the possibility that
similar events could occur in mammals. Tan et al. [16] have also
found that alternatively spliced transcripts can have distinct
pharmacological profiles as well as altered gating characteristics.
In mammals, mutually exclusive exon usage also occurs. The
SCN3A (NaV1.3) channel exists as an embryonic or adult spliced
form, with different exons that code for the S3 and S4 segments in
domain one of the rat channel. A similar pattern is present with
SCN9A, where some differences in biophysical properties and the
effects of cAMP on splice variants have been described [17]. A
unique repertoire of sodium channel splice variants has been
catalogued in DRG [18]. The presence of a transcript with a three
exon repeat encoding NaV1.8 is enhanced by treatment with
NGF, suggesting that this neurotrophin may regulate trans-
splicing events in these cells [19]. All of these regulatory events are
the subject of studies to assess their functional significance.
CNS Pain Pathways and Pain Perception
Neural correlates of consciousness have been the focus of much
attention, especially with the advent of functional imaging. Pain
perception seems to involve a variety of discrete CNS structures
[20]. Attempts to map ascending pain pathways using genetic
approaches have been made [21], and there is now an
appreciation of the complexity of central pain processing that
involves a number of anatomically defined regulatory pathways
[3]. The relationship between the level of pain perceived and the
amount of input into the CNS generated by damage sensing
neurons is extremely complex. The sensory–discriminatory and
affective–evaluative elements that determine the nature of pain
perception have been associated with distinct brain areas, but few
genetic studies have attempted to address these complex issues (a
study of genetic variants of COMT that influence the activities of
endogenous opioids is discussed in Box 2). The difficulty of using
genetic approaches to study central pain perception is underlined
by studies from the Mogil group demonstrating empathic changes
in pain thresholds in transgenic mice observing other mice in pain
[22].
Altered Pain States
Altered pain states, such as inflammatory hyperalgesia and
neuropathic allodynia, are discussed in Box 3. Genetic approaches
have proved valuable in revealing the mechanisms by which these
states arise and are maintained.
Mammalian Genetics
A wide variety of pain assays have been developed for the
mouse, examining different pain modalities. Models of inflamma-
tory and neuropathic pain are also well-described, and may have
more relevance to human clinical conditions than assays of acute
pain. These models have been discussed in detail by the Mogil
group [23–25].
The variety of strains of Mus musculus means that the extent of
genetic contributions to disease can be evaluated. For example,
work on behaviour in response to various pain modalities [26,27]
identified three distinct clusters of nociception, each controlled by
distinct genetic factors. Strain differences can also be used to map
quantitative trait loci affecting pain thresholds.
For the investigation of the function of specific DNA sequences,
transgenic and gene targeting techniques have proved useful.
Examples of transgenics that have generated insights into pain
pathways are numerous, and include reports of modulation of pain
behaviour by the overexpression of the neuropeptide galanin [28],
and the enhancement of inflammatory pain by overexpression of
the NMDA receptor subunit N2RB in the forebrain [29]. Gene
targeting, particularly exploiting the site-specific Cre-loxP recom-
bination system to effect conditional gene deletion, has been
productive [30]. Temporal control of gene expression is also
possible, using inducible Cre constructs to delete loxP-flanked
sequences upon chemical induction of Cre expression [31,32].
Gene deletion in the mouse has proved particularly valuable to the
study of pain pathways. For example, a mouse lacking SCN10A,
the gene encoding the voltage-gated sodium channel NaV1.8, was
recently reported to have almost complete insensitivity to cold pain
[10]. The Mogil group have created a database of existing animals
in increased response to subsequent inputs. Additionally, microglia resident in the spinal cord respond to damage or inflammation by releasing
growth factors and cytokines that alter the excitability of spinal neurons. In certain cases, this can lead to the ongoing activation of pain pathways.
Brain Derived Neurotrophic Factor (BDNF), fractalkine, and chemokines have been invoked as important mediators. Descending input from the brain
to the spinal cord can both inhibit and facilitate the transmission of information in nociceptive circuits. From the spinal cord, information is
transmitted to the brain stem via nociceptor-specific and wide dynamic range projection neurons. It is then processed by a pain matrix of multiple
brain regions, resulting in both sensory-discriminative and affective pain perception ([3], reviewed in [20]). Pain pathways in the CNS are modulated
by endogenous opioid peptides and arachidonic acid metabolites, acting through G-protein coupled receptors (opioid receptors and cannabinoid
receptors) to limit neuronal excitability. GABAergic pathways also act to regulate the excitability of neuronal circuits involved in pain perception.
doi:10.1371/journal.pgen.1000086.g001
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relevant to the study of pain [4]. This database, regularly updated
and currently containing more than 230 genes, is a valuable
resource to the research community. Gaveriaux-Ruff and Kieffer
[33] have also catalogued neuronal Cre lines that are relevant to
genetic studies of pain pathways.
Box 1. Activation of the Pain System
Heterologous expression studies have identified a number of
sensory neuron–associated genes that have been invoked as
sensors for different sorts of damaging stimuli.
Cold Pain
Several mechanisms have been proposed for the transduction of
noxious cold stimuli, including direct activation of specific TRP
channels, inhibition of K+ currents, and reduction of electrogenic
pump activity. Recent work suggests that TRPM8 and TRPA1 may
play important roles in the detection of noxious cold, and that the
inhibition of an as-yet-unidentified background K+ channel may
be important. In addition to current research focusing on
transduction by primary sensory neurons, recent reports have
suggested that epidermal cells, particularly keratinocytes, may be
responsible for the transduction of certain stimuli, synapsing with
primary sensory neurons (see recent review from [74]). Other
studies have proposed a role for vascular nociceptors in cold pain,
suggesting that cold-induced vasoconstriction may begin this
process [43]. It seems clear that our understanding of cold
transduction is still incomplete.
The discovery that the voltage-gated sodium channel NaV1.8
(SCN10A) is not inactivated by cooling, in contrast to all other
voltage-gated sodium channels, provides an insight into the
mechanisms behind the detection of noxious cold [10]. It provides
a clear explanation for the observation that while non-nociceptive
sensory neurons become inactive upon cooling, resulting in
numbness, nociceptors are sensitised. The evolutionary conserva-
tion of NaV1.8 reflects the vital importance of the ability to detect
noxious stimuli in cold environments, particularly relevant to cold-
blooded animals. A more detailed treatment of the mechanisms
involved in cold pain is given in [75].
Heat Pain
The identification of a cation selective ion channel, TRPV1,
expressed in sensory neurons and activated by both heat and
red hot chili peppers (the capsaicin receptor), caught the public
imagination and suggested that the mechanism for noxious
thermosensation had been identified [76]. Despite strong
evidence of a role for TRPV1 in altering inflammatory pain
thresholds, the evidence that noxious heat is transduced solely or
principally by TRPV1 is weak [77,78]. Subsets of thermosensitive
neurons defined by isolectin binding (IB4) have been shown not
to express TRPV1 or TRPV2. TRPV1 knock-outs have fairly normal
patterns of responses to acute noxious heat [77]. TRPV4 seems to
have a more significant role in mechanosensation rather than
thermosensation [63], but the (perhaps inappropriate) epithet
thermoTRPs has been attached to these pleiotropic sensors that
are involved in many aspects of sensation. It seems clear that
other transducers of noxious heat, either in the skin or in neurons,
remain to be identified.
Touch and Noxious Mechanosensation
Sensory neurons express ion channels that can be directly
activated by mechanical stimuli, and evidence has been presented
that such channels underlie noxious mechanosensation [79]. The
genes encoding such transducing channels, however, have not
been identified. Although some electrical deficits in neuronal
responses to mechanical stimuli have been observed in mouse
knock-outs (e.g., ACCN3 encoding ASIC 3, as described by [80]),
there are no known deficits in potential transducing channels,
apart from TRPV4 [32], that show effects on behavioural responses
to noxious mechanical stimuli. Loss of sensory neurons, or
downstream sodium channels characteristically expressed by
these neurons (e.g, SCN9A and SCN10A), do have a mechano-
insensitive phenotype [6,11], implying that these neurons are
responsible for mechanosensation.
Box 2. Pain-Linked SNPs in COMT (catechol-O-
methyltransferase)
Many SNPs affecting pain perception have been identified in
recent years. Possibly the best-characterised of these are the SNPs
present in COMT, the gene coding for catechol-O-methyltransfer-
ase (COMT). COMT mediates the inactivation of catecholamine
neurotransmitters, including dopamine, adrenaline, and noradren-
aline, and reduced COMT enzymatic activity appears to result in
increased pain sensitivity and temporal summation of pain [26].
The precise mechanism by which this occurs has yet to be defined,
although Zubieta et al. [65] propose a depletion of enkephalins
due to elevated dopamine levels, leading to an upregulation of m-
opioid receptors and increased sensitivity to temporally integrated
noxious stimulation. Alternatively, or perhaps additionally, de-
creased adrenaline metabolism (due to decreased COMT activity)
may increase pain through the stimulation of b2/3-adrenergic
receptors, since the pain induced by pharmacological COMT
inhibition is blocked by combined b2/3-adrenergic receptor
antagonists [27]. Zubieta et al. [65] investigated the effect on
pain sensitivity of an abundant, nonsynonymous SNP in COMT.
This SNP results in the substitution of valine by methionine at
position 158 (val158met), and is associated with reduced thermo-
stability and a 3–4-fold reduction in COMT activity. Humans
homozygous for the met158 allele reported very slightly increased
sensory and affective ratings of pain in response to muscular
infusion of hypertonic saline compared to heterozygotes, while
ratings for val158 homozygotes were lower than heterozygotes.
Corresponding variations in regional, pain-related m-opioid
responses were observed using positron emission tomography,
and were taken to explain the differences in pain perception [65].
A broader investigation of the influence of SNPs in the COMT
gene on pain sensitivity provided a more comprehensive picture.
Diatchenko et al. [26] selected six SNPs with high polymorphism
frequency: two synonymous and one nonsynonymous (val158met) in
the coding region, two in the promoter region, and one at the end
of the 39 UTR; no other SNPs exist in the coding region at frequency
.0.15%. Two of these (not including val158met) were found to be
associated with altered pain sensitivity, present in the same
haploblock. The haplotype at this haploblock was found to have a
significant effect on pain perception, with haplotypes designated as
high, low, or intermediate pain sensitivity (population frequencies
10.7%, 36.5%, and 48.7%, respectively). This was found to correlate
inversely with levels of COMT activity. Different combinations of
these haplotypes were strongly associated with variations in
experimental pain sensitivity. Additionally, a reduction in risk of a
common painful musculoskeletal condition, temporomandibular
joint disorder, was observed in the presence of even a single low-
sensitivity haplotype. The mechanism by which these COMT
haplotypes influence activity was recently uncovered using in silico
modelling of mRNA secondary structures. It was found that the
haplotypes differed with respect to mRNA local stem-loop
structures, and that the most stable structure resulted in lower
protein levels and thus activity. Further evidence was provided by
site-directed mutagenesis, restoring normal levels of activity by
eliminating the stable structure [81]. This illustrates two points: first,
that synonymous polymorphisms may have large influences on
protein activity; and second, the potential for interaction of multiple
SNPs and therefore the importance of investigating haplotypes over
single SNPs.
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Genetics of Pain in Man
Substantial variations in both pain sensitivity and susceptibility
to chronic painful conditions occur between individuals in both
human and animal populations [34,23]. For example, human pain
ratings of a given thermal stimulus can encompass the entire range
of the visual-analogue scale (VAS) [34], from ‘‘almost no pain’’ to
‘‘the worst pain imaginable.’’ Pain hypersensitivity may reduce
quality of life and is associated with increased susceptibility to
chronic pain [35]. High pain thresholds may appear desirable, but
may limit protective behaviour in response to injury or hinder
clinical intervention in disease.
These natural variations in propensity to pain result from a
combination of environmental and genetic influences on pain-
sensing systems. Environmental factors, such as early exposure to
acute painful stimuli, can have long-term effects on nociceptive
thresholds in both animals and humans. Perinatal painful events
such as circumcision without anaesthesia, for example, have been
reported to increase sensitivity to pain in later life [36], and are
therefore likely to account for a proportion of the natural
variability in pain perception. As discussed earlier in this review,
loss- or gain-of-function genetic mutations can result in complete
insensitivity to painful stimuli, or in spontaneous pain disorders
(e.g., [7,8]). It therefore appears plausible that more subtle,
quantitative differences in pain sensitivity may also have a genetic
basis. Gender differences in pain sensitivity have been widely
reported and are discussed in Box 4.
Human Heritable Pain Conditions
Heritability studies using sensory testing of twins can identify the
importance of genetic contributions to pain traits, and SNP
association studies have correlated a number of genes with altered
pain behaviour (see Table 1). In contrast, some rare recessive
conditions found in societies that practice consanguineous
marriage lead to alterations in pain thresholds, and the genes that
underlie such conditions are of major interest. Selective cell loss of
peripheral neurons is a characteristic of many pain insensitivity
syndromes [37]. The hereditary sensory and autonomic neurop-
athies HSAN1-4 are all examples of syndromes where pain
behaviour is diminished, and some sensory loss also occurs. Table 2
summarises currently known heritable pain conditions.
Despite the fact that most of these syndromes involve cell death,
and are thus unappealing in terms of drug development, they have
provided important insights into aspects of pain signalling. For
example, HSAN-3 demonstrates the essential role of NGF-
dependent sensory neurons in the pain process, whilst the recent
discovery of the NaV1.7-encoding SCN9A gene as an essential
component of human pain provides an exciting new analgesic
drug target.
Contribution of Genetics to Pain Thresholds
Several studies have attempted to evaluate the relative contribu-
tions of genetics and environment to variations in pain sensitivity, in
both animals and humans. Comparisons of pain thresholds (over 12
modalities) within and between 11 inbred laboratory mouse strains
revealed genetic contributions of between 30% and 76% [23–25].
The experimental power of these studies was high due to the lack of
environmental variability and the relatively large genetic differences
between strains, meaning that these results are likely to represent the
maximum contribution of genetic factors to pain perception. This
contribution, however, appears to be dependent on both severity and
modality of stimulus, with three major clusters of nociception
identified [23,24]. These clusters were defined as ‘‘assays of baseline
thermal nociception,’’ ‘‘spontaneously-emitted responses to chemical
stimuli,’’ and ‘‘baseline mechanical sensitivity and cutaneous
hypersensitivity.’’ Surprisingly, acute thermal and mechanical
nociception were found to be strongly negatively correlated [24].
While there is a body of literature supporting distinct pathways for
these modalities, including different primary afferent and central
neurons, differential opioid modulation, and possibly different spinal
cord lamina neuron location, this would be expected to result in a
Box 3. Altered Pain States
Clinical problems associated with the pain system occur when
pain thresholds are dramatically altered so that noxious insults
became extremely painful (hyperalgesia) or non-noxious stimuli,
such as light touch or mild cold, also become very painful
(allodynia). Hyperalgesia is commonly found in inflammatory pain
conditions where damaged tissue is infiltrated with immune
system cells, and a variety of soluble mediators that act on
peripheral neurons are released. Allodynia may occur when nerves
themselves are damaged—this is neuropathic pain, which occurs
in situations such as diabetic neuropathy, HIV-associated neurop-
athy, or following physical trauma. Studies have identified a
number of critical regulators of altered pain states, including
genes not normally expressed in the nervous system, but present in
cells of the immune system that also are activated in situations of
tissue damage. For example, P2X7 (P2RX7), an ATP receptor absent
from neurons, is essential for altered inflammatory or neuropathic
pain [82]. This receptor is found on macrophages and microglia
together with P2X4, and is a likely source of the soluble mediators
that affect neuronal excitability in peripheral and central neurons
during neuropathic pain. Damaged peripheral neurons recruit
activated microglia to the dorsal horn, probably through the same
mechanisms that act on peripheral immune cells, with unfortunate
consequences for central pain processing [83]. A comprehensive
pain database that deals with all pain-related knock-outs can be
found at http://paingeneticslab.ca/4105/06_02_pain_genetics_da-
tabase.asp.
Many inflammatory mediators (e.g., IL-1 and PGE2) act directly
on sensory neurons and through cascades of second messengers
and kinases, altering the sensitivity of both primary transducing
receptors and sodium channels required for action potential
transmission [84]. A pivotal role for TRPA1 in detecting environ-
mental irritants has recently been identified [56,57].
Box 4. Gender Differences in Pain Perception
Gender differences in pain perception have been reported by
many studies, in both animals and humans. For example, women
are more likely to suffer from a variety of chronic pain disorders,
including fibromyalgia, complex regional pain syndrome, and
trigeminal neuralgia. Experimentally, pain thresholds for pressure
pain and electrical stimulation have been shown to be lower for
females than for males, while less variation has been observed for
thermal pain stimuli. For a detailed treatment of gender
differences in pain perception, see the recent and comprehensive
review from Greenspan et al. [85]. A proportion of these variations
may result from genetic differences at loci on the sex chromo-
somes. Gonadal factors such as testosterone and estradiol
modulate sensitivity to pain and analgesia [86], resulting in
gender differences in pain perception. Mogil et al. [87] reported
that certain sex differences in pain and analgesia appear
genetically mediated. The investigation of genetically linked
factors affecting pain sensitivity, however, is confounded by
contributions of gender to disease processes, and by societal
influences. Nevertheless, several interesting findings have been
reported, including greater opioid-induced analgesia in males
than females [88,89].
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lack of correlation. Negative correlation implies the presence of
common pathways acting in opposing directions, or in a competitive
manner. For example, a particular factor may sensitise mechanical
but reduce thermal nociception, with high- and low-expressing
strains resulting in the negative correlation observed. These
nociceptive clusters may have a physiological basis. Sensitivity to
analgesics, including gabapentin, morphine, and NSAIDS, is also
affected by genetic factors in rodents [38]. For example, variations in
the melanocortin-1 receptor gene have been shown to affect m-opioid
analgesia in both mice and humans [39], and KCNJ9 (GIRK3) has
been identified as a locus affecting analgesia from multiple drug
classes [40].
In humans, the genetic contribution to variation in pain
sensitivity has been investigated using twin studies, comparing
correlation of pain thresholds between monozygotic (shared
genetic and environment) and dizygotic (shared environment)
twins. Two recent papers investigating responses to experimentally
induced pain reported genetic contributions to sensitivity to the
majority of pain modalities. Norbury et al. [41] performed
quantitative sensory testing on almost 100 pairs of female twins,
using a wide range of noxious stimuli and including models of
hyperalgesia and allodynia. Genetic components of 22%–55%
were reported for the majority of painful stimuli, particularly heat
pain thresholds, including burn, burn-evoked mechanical allody-
nia, and iontophoresis of acid or ATP. Nielsen et al. [42]
performed a similar study, investigating the genetic contribution to
contact heat and cold pressor painful stimuli in a similar sample
size. Sixty percent of the variance in cold pressor pain was
predicted to be genetically mediated, compared with only 26% of
the variance in heat pain. Interestingly, the factors influencing
pain ratings were only loosely correlated between pain modalities,
with genetic factors common to both modalities accounting for
only 7% and 3% of the variance in cold pressor and heat pain,
respectively. This is likely to be due to the nature of the cold
stimulus used in this study, acting mainly through venous rather
than cutaneous nociceptors [43] and therefore through a distinct
neuronal pathway. Alternatively, the low correlation may reflect
genetically encoded differences in primary transduction mecha-
nisms. The differences in genetic contributions to various pain
modalities in humans may reflect the distinct types of nociception
described by Mogil et al. [24], probably representing peripheral or
central mechanistic differences in the perception of different pain
Table 1. SNPs Suggested To Affect Human Pain Sensitivity.
Gene Protein Mutation Phenotype Example Reference(s)
GCH1 GTP cyclohydrolase Multiple SNPs Partial analgesia [35]
COMT Catechol-O-methyltransferase Multiple SNPs Increased/decreased pain sensitivity [26,58,65,66]
OPRM1 Opioid receptor m1 Multiple SNPs Decreased pain sensitivity, decreased opioid analgesia [52,53]
OPRD1 Opioid receptor d1 Multiple SNPs Increased/decreased pain sensitivity [67]
MC1R Melanocortin 1 receptor Loss of function SNPs? Partial analgesia, increased analgesic responsiveness [39,68]
TRPA1 Transient receptor potential A1 Multiple SNPs Increased pain sensitivity [58]
TRPV1 Transient receptor potential V1 SNP Decreased pain sensitivity [67,69]
CYP2D6 Cytochrome P450 2D6 Multiple SNPs Altered analgesic efficacy [59]
ABCB1 ATP-binding cassette, B1 SNP Altered morphine sensitivity [61]
FAAH Fatty acid amide hydrolase Multiple SNPs Increased pain sensitivity [58]
doi:10.1371/journal.pgen.1000086.t001
Table 2. Heritable Pain Conditions.
Syndrome Gene Affected Cell Loss Phenotype Reference
HSAN-1 Autosomal dominant mis-sense mutations
in serine palmitoyltransferase long chain
base subunit 1 (SPTLC1)
Apoptotic cell loss of sensory and
other neurons
Pain and heat loss [70]
HSAN-2 Mis-sense mutations in the protein kinase
PRKWNK1
Developing sensory cell loss Developing loss of all sensation [71]
HSAN-3 (Familial
dysautonomia)
Splicing deficit in IkbKAP protein Failure in sensory neuron
development
Pain-free phenotype [72]
HSAN-4 (CIPA) Loss of functional NGF receptor TrkA Loss of most small diameter
sensory neurons
Congenital insensitivity to pain [1]
Mutilated foot rat d subunit of the (Cct4 ) gene Loss of nociceptors Ulceration and loss of pain
sensitivity
[73]
Erythermalgia Point mutations in sodium channel
NaV1.7 – increased excitability
No cell loss Chronic inflammation [9]
Paroxysmal extreme pain
(familial rectal pain)
Point mutations in NaV1.7 - loss of
inactivation
No cell loss Mechanically induced extreme pain [8]
Insensitivity to pain Mis-sense mutations in NaV1.7 No cell loss Complete insensitivity to acute pain [7]
doi:10.1371/journal.pgen.1000086.t002
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modalities. Genetic factors affecting multiple modalities of pain
perception, in contrast, may represent common mechanisms in
primary afferent neurons or central pain pathways.
In addition to experimentally induced pain, several studies have
investigated the contribution of genetic variability to differences in
severity of and susceptibility to chronic pain conditions. For
example, a recent study, using 15,950 pairs of twins, found a
genetic contribution of about 50% to the likelihood of developing
fibromyalgia, a relatively prevalent chronic pain condition [44].
The importance of genetic contributions to chronic pain has also
been illustrated using rodent models of inflammatory and
neuropathic pain [45,46].
Mechanisms of Genetic Control of Pain Sensitivity
While these studies have been useful in defining the importance of
genetic variation in differences in pain perception, they do not
provide mechanistic explanations of these differences. Analysis of
clinically presenting, congenital disorders of pain sensation can
define genes central to the ability to detect noxious stimuli, but rely
on the resulting phenotype being relatively conspicuous. Quantita-
tive trait locus (QTL) mapping (discussed in [47]), which identifies
regions of the genome associated with variation in a particular trait,
is one way in which genetic factors responsible for smaller variations
in pain sensitivity can be detected. This technique has been used
extensively by Mogil and others to define areas of the murine
genome contributing to pain sensitivity (e.g., [48,49]). Using fine
mapping, areas of ,1–5 centiMorgans can be defined [47]. In
addition, a number of papers analysing QTL contributions to
analgesia have been published [50].
Following identification of loci associated with variability in pain
sensitivity, the analysis of single nucleotide polymorphisms (SNPs)
can be used to determine more precisely the genetic location
underlying this variability. SNPs are traditionally defined as
having an allele frequency of .1% or .0.5% in the population,
although this is no longer a strict requirement. They may occur
within any part of the genome: coding and noncoding sections of
genes, and in intergenic regulatory or undefined regions. Coding
region SNPs which do not alter the resulting amino acid are
termed synonymous. Although synonymous SNPs do not alter the
sequence of protein produced, they may still result in major
changes in function. For example, they may affect levels of
transcription, splicing, mRNA stability, or regulatory RNA
expression. One mechanism by which this may occur is through
effects of synonymous SNPs on cotranslational folding [51].
Sodium channels are known to be regulated by splicing and
microRNAs with important functional consequences for pain
thresholds. Nonsynonymous SNPs result in an altered amino acid
sequence, with functional consequences that can be more directly
assessed. Since genetic loci are not randomly segregated during
meiosis, sets of SNPs have a tendency to be inherited together.
Particular combinations of linked SNPs are described as
haplotypes (from haploid genotype). This means that an identified
SNP may function as a marker of another linked genetic region
affecting pain processes, rather than as a mechanistic factor.
Additionally, several linked SNPs may affect pain perception,
meaning that haplotype analysis may be more useful than that of
single SNPs for the prediction of pain sensitivity.
Pain-Related SNPs
The study of pain-related SNPs in the human has proved
problematic, due to the tendency of different data sets to yield
conflicting conclusions; in many cases, a finding from one has been
contradicted by those from others. Here, we present a selection of
the positive associations that have been reported, with the caveat
that a number of these findings have not been replicated in other
investigations.
SNPs in several genes have been found to have substantial
impacts on pain sensitivity. These are summarised in Table 1.
Perhaps the most studied of SNPs are those in the gene COMT,
which are discussed in Box 2. Polymorphisms in the m-opioid
receptor gene OPRM1 (A80G, A118G), which mediates the
physiological anti-pain effects of endorphins, have been linked to
variations in experimental pain sensitivity [52,53]. Interestingly,
the A118G SNP in OPRM1 (frequency ,10%) affected both
subjective pain reporting [52] and objective pain-related cortical
activity [53]. Opioid analgesic requirements (representing either
pain intensity or opioid efficacy) in chronic [54] pain are also
affected by this polymorphism, which appears to act by down-
regulating receptor mRNA [55].
The melanocortin-1-receptor gene MC1R contains polymor-
phisms associated with both pain sensitivity and m-opioid analgesia
in humans and mice [39], which also result in red hair and altered
k-opioid analgesia in females. The mechanisms behind these
effects are unclear, but may involve altered m-opioid action.
In a study going from initial pathway identification to human pain
variation, Tegeder et al. [35] recently described the involvement of
tetrahydrobiopterin (BH4, a cofactor in nitric oxide, serotonin, and
catecholamine production) and its synthesising enzyme GTP
cyclohydrolase (GCH-1) in pain sensitivity. Excess BH4 is thought
to increase pain due to increased nitric oxide synthesis. A pain-
protective haplotype (probably consisting of five SNPs in a regulatory
region of the gene) of GTP cyclohydrolase was identified in about
15% of the population studied, shown to decrease both persistent
post-surgical and acute mechanical experimental pain. Subjects
heterozygous or homozygous for the pain-protective haplotype were
found to show reduced upregulation of the GCH1 transcript in
response to cAMP, resulting in lower levels of BH4, suggesting that
altered GCH1 transcriptional modulation underlies the decreased
pain sensitivity observed in these individuals.
Genetic variations in the TRPA1 gene encoding a channel
activated by cold, mustard oil, and possibly mechanical stimula-
tion in nociceptors [56,57], contribute to variations in cold pain
sensitivity [58]. This effect was reported to be gender-dependent,
in agreement with the effect of TRPA1 deletion on cold pain in the
mouse [20]. SNPs in fatty acid amide hydrolase (FAAH), which
inactivates the endocannabinoid anandamide, may also contribute
to variation in pain sensitivity [58].
Genetic Polymorphisms Affecting Analgesia
A range of genetic variations have been identified that alter the
effectiveness of analgesic drugs. In particular, polymorphisms of
the cytochrome P450 enzymes (CYP), which play a key role in the
metabolism of many drugs, can affect the efficacy of opiates, and
NSAIDs. Reduced activity of cytochromes can either reduce or
enhance analgesic efficacy, depending on the activity of the
metabolites compared to the original drug. For example, one
metabolite of the opioid tramadol, O-desmethyltramadol, is a
considerably more potent agonist of the m-opioid receptor than
tramadol, meaning that low metabolisers of tramadol display
reduced analgesia, despite an increased half-life of tramadol being
observed [59]. Altered tramadol metabolism has been linked to
polymorphisms in the gene coding for cytochrome P450 2D6
(CYP2D6), which also associate with reduced effectiveness of this
analgesic [59,60]. Polymorphisms in other cytochrome P450
isoforms also appear to contribute to variations in analgesic
efficacy, generally in a drug-specific manner. Additionally,
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polymorphisms affecting the activity of the multidrug resistance
protein ABCB1 (MDR1), which is a major determinant of
morphine bioavailability, can alter the efficacy of morphine pain
relief [61], presumably by affecting the rate at which morphine
and its metabolites are removed from the cell.
Interestingly, not all genetic variations affect all pain modalities,
meaning that these must be transduced by distinct pathways. The
identification of genetic variations affecting propensity to pain
raises the possibility of discovering new therapeutic targets for
pain. By selecting those polymorphisms affecting pain sensitivity
but not other processes such as cardiac function, the likelihood of
identifying a specific, selective target will be enhanced.
Future Prospects
Substantial progress has been made in pain genetics recently.
Just as a massive research attack on cancer genetics in the 1980s is
now paying dividends in terms of drug treatment, so the genetic
description of key signalling molecules and mediators in the pain
system has provided many new targets (e.g., P2RX7, SCN9A) for
analgesic drugs that are under development. Chronic pain in the
absence of disease is an obvious form of dysfunctional sensation
and provides a useful model system for understanding other
nervous system disorders (schizophrenia, autism) that involve
pathological responses to external sensations. Studies of the
affective component of pain perception, combined with functional
imaging, genetically manipulatable animal models, and new
genetic insights into pain mechanisms offer considerable hope
for our understanding not only of ‘‘pain in the brain’’, but other
aspects of human sensation, consciousness, and behaviour.
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